A new multi-institutional study, led by University Hospitals Connor Whole Health, found that adults with newly diagnosed low ...

Studies evaluate levothyroxine’s impact on cardiovascular disease risk in midlife and older women and in adults with ...

Taiwan: A recent study has found that the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type ...

Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by ...

The use of anticoagulants is not associated with improved overall survival in patients with pulmonary arterial hypertension, ...

Topline data were announced from a pivotal phase 1/2 study evaluating AMT-130 in patients with Huntington disease.

Immunocompromised status may negatively affect survival outcomes in patients with bladder cancer, a study suggests.

The analysis revealed a mixed picture of psychosocial outcomes. Users showed modest but significant increases in affective ...

Qure N.V. (NASDAQ:QURE) on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington’s ...

AMT-130 has been granted Breakthrough Therapy designation and Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.